Wellington Management Group LLP Decreases Position in Insulet Corporation $PODD

Wellington Management Group LLP cut its holdings in Insulet Corporation (NASDAQ:PODD) by 84.5% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 16,744 shares of the medical instruments supplier’s stock after selling 91,010 shares during the period. Wellington Management Group LLP’s holdings in Insulet were worth $2,549,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in PODD. Larson Financial Group LLC grew its stake in shares of Insulet by 114.6% during the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after buying an additional 47 shares during the last quarter. University of Texas Texas AM Investment Management Co. bought a new stake in shares of Insulet in the 4th quarter valued at about $26,000. DV Equities LLC purchased a new stake in Insulet during the 4th quarter valued at about $28,000. Elyxium Wealth LLC purchased a new stake in Insulet during the 4th quarter valued at about $28,000. Finally, Mcguire Capital Advisors Inc. bought a new position in Insulet during the 4th quarter worth approximately $29,000.

Insulet Trading Down 2.3%

PODD opened at $134.68 on Friday. Insulet Corporation has a one year low of $126.40 and a one year high of $354.88. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The business has a 50 day simple moving average of $153.01 and a two-hundred day simple moving average of $174.22. The firm has a market capitalization of $9.34 billion, a price-to-earnings ratio of 25.17, a PEG ratio of 1.09 and a beta of 1.08.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.19. Insulet had a return on equity of 29.29% and a net margin of 12.29%.The firm had revenue of $801.70 million for the quarter, compared to analyst estimates of $787.39 million. During the same period last year, the company earned $1.17 EPS. The business’s quarterly revenue was up 23.5% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.460- EPS. Analysts predict that Insulet Corporation will post 6.51 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have commented on PODD. Benchmark decreased their price target on Insulet from $250.00 to $185.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Truist Financial reissued a “hold” rating and set a $153.00 price objective (down from $210.00) on shares of Insulet in a research note on Wednesday, August 5th. BTIG Research downgraded shares of Insulet from a “buy” rating to a “neutral” rating in a research note on Thursday, August 6th. Stifel Nicolaus lowered their price target on shares of Insulet from $225.00 to $180.00 and set a “buy” rating for the company in a report on Thursday, August 6th. Finally, UBS Group dropped their price target on shares of Insulet from $174.00 to $150.00 and set a “neutral” rating for the company in a research report on Thursday, August 6th. Fourteen research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $195.40.

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s principal product platform is Omnipod, a tubeless, wearable insulin pump system. Omnipod products include the disposable, wearable Pod and related management and smartphone-based technologies.